it expects to be eligible for 180 days' market exclusivity (although this is based on the "first to file"). According to IMS Health, Copaxone generated ~$412M in U.S. sales over the 12-month period ending June 30, 2014. Post your comment!
continued to buck the seasonality factor by bringing in a 2% increase in week over week sales according to industry tracker IMS Health. The fact that Belviq has been able to avoid a dip in sales is a testament to the fact that it is new as well as the fact
Con , for the treatment of patients with hypokalemia , with or without metabolic alkalosis , digitalis intoxication and hypokalemic familial periodic paralysis. According to IMS Health, the U.S. market is ~$135M. Post your comment!
erectile dysfunction (ED), Vitaros ( alprostadil plus excipient), in Germany by Sandoz affiliate Hexal AG. According to IMS Health, the German ED market is ~$150M. Under the terms of its license agreement with Sandoz, Apricus is eligible to receive
ARNA ) investors this week is that scripts were slightly down. The good news this week is that for the first time (using IMS Health numbers) Belviq sales were above the levels reported for Vivus's (NASDAQ: VVUS ) Qsymia. Belviq edged out Qsymia by
prescription nicotine inhaler/insuffation device for smoking cessation, also saw a patent expire this week. A report citing IMS Health data indicates that as of 2011, Nicotrol sales were in the $6 million range, well behind then-market leader Chantix
Facebook Messenger, released after Facebook (NASDAQ: FB ) began requiring users to download a standalone Messenger app to send IMs to Facebook friends, has a rating of just 1/5 stars on the App Store. Over its entire lifetime, the app still has a rating
report having given us some new data, it was once again time to assess adjustments made in the scripts. The 5% adjustment to IMS scripts last quarter resulted in an estimated $4.05 million in revenue for Arena going into the call. Actual revenue Complete
adjustments that will be needed to model good estimates going forward. After the last quarterly call, I lower my upward adjustment to IMS health script numbers from 10% to 5%. Immediately some very passionate Arena investors saw this a a move to downplay sales and
IMS Health Holdings (NYSE: IMS ) Q2 results : Revenue: $662M (+6.1%), Information: $386M (+1.8%), Technology Services: $276M (+12.7%); Cost of Services: $314M (+11.7%); SG&A Expense: $247M (+70.3